Product Images Quetiapine Fumarate

This is a description of a medication called Quetiapine Fumarate. It is available in 300mg tablets, with 60 tablets per bottle. The bottle has an NDC # 43353-0150-53. It should be stored at room temperature (68-77 degrees F). The medication needs to be kept out of reach of children. It is manufactured by Apotex Inc. in Toronto, Canada, and repackaged by Aphena Pharma in Cookeville, TN 38505. There is a USP reference provided as "See USP C: 3X Batch:", but the rest of the text is not easily readable.*

This is a description of a medication called Quetiapine Fumarate, packaged in a bottle containing 60 tablets, each of 25mg. The bottle has a unique tracking code for the drug (NDC # 43353-0153-53) and is manufactured by Apotex Inc. based in Toronto, Canada, and repackaged by Aphena Pharma in Cookeville, TN. The medication needs to be stored between 20-25 degrees Celsius (68-77 degrees Fahrenheit) and kept out of the reach of children. The label also includes instructions to dispense the medication by USP.*

This is a label of a medication called Quetiapine Fumarate. It is a pack of 60 tablets of 100mg concentration. It includes the manufacturer details and the repackaging details. The label provides directions to store the medication at room temperature and out of reach of children. The batch number and lot number are also provided on the label.*

This is a bottle of Quetiapine Fumarate containing 60 tablets of 200mg each, with the NDC # 43353-0161-53. It is manufactured by Apotex Inc. in Toronoto, Canada, and repackaged by Aphena Pharma in Cookeville, TN. It should be stored at room temperature (68-77 degrees F) and kept out of reach of children. The prescription is subject to USP Dispense definition. There is a lot and batch number indicated on the bottle but they are not readable due to errors.*

The text describes a figure showing Kaplan-Meier curves representing the time to recurrence of a mood event in a study with 100 participants. The x-axis represents time (in an unspecified unit) and the y-axis represents the proportion of patients with relapse, expressed as a percentage. The curve appears to plateau towards the end of the follow-up period.*